联合免疫治疗方法治疗胰腺癌。
Combination Immunotherapy Approaches for Pancreatic Cancer Treatment.
机构信息
School of Pharmaceutical Sciences & Yunnan Provincial Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming, Yunnan, China.
The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
出版信息
Can J Gastroenterol Hepatol. 2018 Mar 7;2018:6240467. doi: 10.1155/2018/6240467. eCollection 2018.
Abstract
Pancreatic ductal adenocarcinoma is a lethal malignant disease with a very low medium survival. Currently, metastatic pancreatic cancer poorly responds to conventional treatments and exhibits an acute resistance to most chemotherapy. Few approaches have been shown to be effective for metastatic pancreatic cancer treatment. Novel therapeutic approaches to treat patients with pancreatic adenocarcinoma are in great demand. Last decades, immunotherapies have been evaluated in clinical trials and received great success in many types of cancers. However, it has very limited success in treating pancreatic cancer. As pancreatic cancer poorly responds to many single immunotherapeutic agents, combination immunotherapy was introduced to improve efficacy. The combination therapies hold great promise for enhancing immune responses to achieve better therapeutic effects. This review summarizes the existing and potential combination immunotherapies for the treatment of pancreatic cancer.
摘要
胰腺导管腺癌是一种致命的恶性疾病，中位生存期非常低。目前，转移性胰腺癌对常规治疗反应不佳，并且对大多数化疗药物表现出急性耐药性。很少有方法被证明对转移性胰腺癌的治疗有效。因此，人们非常需要新的治疗方法来治疗胰腺腺癌患者。过去几十年，免疫疗法已在临床试验中进行了评估，并在许多类型的癌症中取得了巨大成功。然而，它在治疗胰腺癌方面的成功非常有限。由于胰腺癌对许多单一免疫治疗药物反应不佳，因此引入了联合免疫疗法以提高疗效。联合疗法有望增强免疫反应，从而获得更好的治疗效果。本综述总结了用于治疗胰腺癌的现有和潜在的联合免疫疗法。
相似文献
1
Combination Immunotherapy Approaches for Pancreatic Cancer Treatment.联合免疫治疗方法治疗胰腺癌。
Can J Gastroenterol Hepatol. 2018 Mar 7;2018:6240467. doi: 10.1155/2018/6240467. eCollection 2018.
2
T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.与免疫治疗治疗后的胰腺导管腺癌患者生存相关的 T 细胞受体库特征。
JCI Insight. 2018 Jul 12;3(13):122092. doi: 10.1172/jci.insight.122092.
3
Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress.现代免疫疗法在胃肠道恶性肿瘤中的作用：当前临床进展综述
J Hematol Oncol. 2017 Apr 24;10(1):86. doi: 10.1186/s13045-017-0454-7.
4
Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy.胰腺癌：聚焦免疫治疗的当前观点
Crit Rev Oncog. 2019;24(2):105-118. doi: 10.1615/CritRevOncog.2019031417.
5
Immunotherapy in genitourinary malignancies.泌尿生殖系统恶性肿瘤的免疫治疗
J Hematol Oncol. 2017 Apr 24;10(1):95. doi: 10.1186/s13045-017-0457-4.
6
[Not Available].[无可用内容]
Bull Cancer. 2018 Dec;105 Suppl 1:S68-S79. doi: 10.1016/S0007-4551(18)30392-8.
7
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients.一项个体化自体树突状细胞疫苗、阿司匹林联合标准辅助化疗，序贯纳武利尤单抗治疗可切除胰腺导管腺癌的 Ib 期研究：三例患者的抗原发现可行性验证
Front Immunol. 2019 Aug 8;10:1832. doi: 10.3389/fimmu.2019.01832. eCollection 2019.
8
Immunotherapy for osteosarcoma: Where do we go from here?骨肉瘤的免疫治疗：我们的路在何方？
Pediatr Blood Cancer. 2018 Sep;65(9):e27227. doi: 10.1002/pbc.27227. Epub 2018 Jun 19.
9
Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.拓宽免疫疗法在胰腺癌中的应用：挑战与机遇。
Gastroenterology. 2019 May;156(7):2056-2072. doi: 10.1053/j.gastro.2018.12.038. Epub 2019 Jan 18.
10
Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.胰腺癌：免疫系统在癌症进展及基于疫苗的免疫治疗中的作用
Hum Vaccin Immunother. 2014;10(11):3354-68. doi: 10.4161/hv.34392.
引用本文的文献
1
Disulfidptosis classification of pancreatic carcinoma reveals correlation with clinical prognosis and immune profile.胰腺癌的二硫化物诱导细胞程序性坏死分类揭示了与临床预后和免疫特征的相关性。
Hereditas. 2025 Feb 22;162(1):26. doi: 10.1186/s41065-025-00381-z.
2
Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality?用疫苗为基础的联合疗法对抗胰腺癌：希望还是现实？
Cells. 2024 Sep 16;13(18):1558. doi: 10.3390/cells13181558.
3
Enhancement of Tumorigenicity, Spheroid Niche, and Drug Resistance of Pancreatic Cancer Cells in Three-Dimensional Culture System.三维培养系统中胰腺癌细胞致瘤性、球状体微环境及耐药性的增强
J Cancer. 2024 Mar 2;15(8):2292-2305. doi: 10.7150/jca.87494. eCollection 2024.
4
The expression profile of Gasdermin C-related genes predicts the prognosis and immunotherapy response of pancreatic adenocarcinoma.Gasdermin C相关基因的表达谱可预测胰腺腺癌的预后及免疫治疗反应。
Am J Cancer Res. 2023 Apr 15;13(4):1240-1258. eCollection 2023.
5
Evaluation of autophagy inhibition to combat cancer: (vanadium complex)-protein interactions, parameterization, and validation of a new force field.评估自噬抑制在抗癌方面的作用：（钒配合物）-蛋白质相互作用、参数化和新力场的验证。
J Mol Model. 2023 Mar 30;29(4):123. doi: 10.1007/s00894-023-05530-7.
6
Efficacy of bivalent 1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice.二价1BBL基因疫苗联合抗PD1抗体在小鼠MC38肿瘤模型中的疗效
Heliyon. 2022 Sep 28;8(10):e10775. doi: 10.1016/j.heliyon.2022.e10775. eCollection 2022 Oct.
7
System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma.基于细胞焦亡相关基因的系统分析鉴定 GSDMC 为胰腺腺癌的一个新治疗靶点。
J Transl Med. 2022 Oct 5;20(1):455. doi: 10.1186/s12967-022-03632-z.
8
Potential of Gold Nanoparticle in Current Radiotherapy Using a Co-Culture Model of Cancer Cells and Cancer Associated Fibroblast Cells.使用癌细胞与癌症相关成纤维细胞共培养模型研究金纳米颗粒在当前放射治疗中的潜力。
Cancers (Basel). 2022 Jul 22;14(15):3586. doi: 10.3390/cancers14153586.
9
High Dose Local Photon Irradiation Is Crucial in Anti-CTLA-4 Antibody Therapy to Enhance the Abscopal Response in a Murine Pancreatic Carcinoma Model.高剂量局部光子照射在抗CTLA-4抗体疗法中对增强小鼠胰腺癌模型的远隔效应至关重要。
Cancers (Basel). 2022 Apr 22;14(9):2087. doi: 10.3390/cancers14092087.
10
Next Generation of Cancer Drug Repurposing: Therapeutic Combination of Aspirin and Oseltamivir Phosphate Potentiates Gemcitabine to Disable Key Survival Pathways Critical for Pancreatic Cancer Progression.下一代癌症药物重新利用：阿司匹林与磷酸奥司他韦的治疗组合增强吉西他滨的作用，以阻断对胰腺癌进展至关重要的关键生存途径。
Cancers (Basel). 2022 Mar 8;14(6):1374. doi: 10.3390/cancers14061374.
本文引用的文献
1
CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer.CTLA-4/CD80通路调节T细胞浸润至胰腺癌中。
Cancer Immunol Immunother. 2017 Dec;66(12):1609-1617. doi: 10.1007/s00262-017-2053-4. Epub 2017 Aug 30.
2
CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.靶向实体瘤的嵌合抗原受体T细胞：癌胚抗原（CEA）被证明是一个安全的靶点。
Cancer Immunol Immunother. 2017 Nov;66(11):1505-1507. doi: 10.1007/s00262-017-2045-4. Epub 2017 Jul 28.
3
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).帕博利珠单抗联合化疗用于晚期癌症患者的Ib期研究（PembroPlus）。
Br J Cancer. 2017 Jun 27;117(1):33-40. doi: 10.1038/bjc.2017.145. Epub 2017 Jun 6.
4
Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance.半乳糖凝集素9对巨噬细胞上Dectin 1的激活促进胰腺癌及肿瘤周围免疫耐受。
Nat Med. 2017 May;23(5):556-567. doi: 10.1038/nm.4314. Epub 2017 Apr 10.
5
Next frontiers in CAR T-cell therapy.嵌合抗原受体T细胞疗法的下一个前沿领域。
Mol Ther Oncolytics. 2016 Nov 30;3:16028. doi: 10.1038/mto.2016.28. eCollection 2016.
6
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.靶向膜黏蛋白MUC1的癌症相关Tn糖型的工程化嵌合抗原受体T细胞可控制腺癌。
Immunity. 2016 Jun 21;44(6):1444-54. doi: 10.1016/j.immuni.2016.05.014.
7
CAR T Cell Therapy: A Game Changer in Cancer Treatment.嵌合抗原受体 T 细胞疗法：癌症治疗的变革者。
J Immunol Res. 2016;2016:5474602. doi: 10.1155/2016/5474602. Epub 2016 May 19.
8
Pancreatic cancer.胰腺癌。
Lancet. 2016 Jul 2;388(10039):73-85. doi: 10.1016/S0140-6736(16)00141-0. Epub 2016 Jan 30.
9
T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma.针对天然抗原设计的T细胞可克服免疫和物理屏障以治疗胰腺导管腺癌。
Cancer Cell. 2015 Nov 9;28(5):638-652. doi: 10.1016/j.ccell.2015.09.022. Epub 2015 Oct 29.
10
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.靶向间皮素的嵌合抗原受体：驱动T细胞作用于实体瘤。
Cancer Discov. 2016 Feb;6(2):133-46. doi: 10.1158/2159-8290.CD-15-0583. Epub 2015 Oct 26.
Zotero 插件